Salekeen Rahagir, Haider Abu Nasim, Akhter Fouzia, Billah Md Morsaline, Islam Md Emdadul, Didarul Islam Kazi Mohammed
Biotechnology and Genetic Engineering Discipline, Life Science School, Khulna University, Khulna, 9208, Bangladesh.
Biotechnology Program, Department of Mathematics and Natural Sciences, BRAC University, Dhaka, 1212, Bangladesh.
Int J Cardiol Cardiovasc Risk Prev. 2022 Aug 4;14:200143. doi: 10.1016/j.ijcrp.2022.200143. eCollection 2022 Sep.
A marked increase in the global prevalence of ischemic heart disease demands focused research for novel and more effective therapeutic strategies. At present, atherosclerotic cardiovascular disease (ACVD) is the leading cause of the global incidence of heart attacks and a major contributor to many peripheral cardiac diseases. Decades of research have unearthed the complex and multidimensional pathophysiology of ACVD encompassing oxidative stress, redox imbalance, lipid peroxidation, pro-inflammatory signaling, hyperglycemic stress and diabetes mellitus, chronic low-grade inflammation and aging, immune dysregulation, vascular dysfunction, loss of hemostasis, thrombosis, and fluid shear stress. However, the scientific basis of therapeutic interventions using conventional understandings of the disease mechanisms has been subject to renewed scrutiny with novel findings in recent years. This critical review attempts to revise the pathophysiological mechanisms of atherosclerosis using a recent body of literature, with a focus on lipid metabolism and associated cellular and biochemical processes. The comprehensive study encompasses different molecular perspectives in the development and progression of coronary atherosclerosis. The review also summarizes currently prescribed small molecule therapeutics in inflammation and ACVD, and overviews prospective management measures under development including peptides and microRNA therapeutics. The study provides updated insights into the current knowledge of coronary atherosclerosis, and highlights the need for effective prevention, management and development of novel intervention approaches to overcome this chronic epidemic.
全球缺血性心脏病患病率显著上升,这需要针对新的、更有效的治疗策略开展重点研究。目前,动脉粥样硬化性心血管疾病(ACVD)是全球心脏病发作发病率的主要原因,也是许多外周心脏疾病的主要促成因素。数十年的研究揭示了ACVD复杂且多维度的病理生理学,包括氧化应激、氧化还原失衡、脂质过氧化、促炎信号传导、高血糖应激与糖尿病、慢性低度炎症与衰老、免疫失调、血管功能障碍、止血功能丧失、血栓形成以及流体剪切应力。然而,近年来新的研究发现对基于传统疾病机制理解的治疗干预措施的科学依据进行了重新审视。这篇批判性综述试图利用近期的文献对动脉粥样硬化的病理生理机制进行修正,重点关注脂质代谢以及相关的细胞和生化过程。这项全面研究涵盖了冠状动脉粥样硬化发生和发展过程中的不同分子视角。该综述还总结了目前针对炎症和ACVD所开具的小分子疗法,并概述了正在研发的前瞻性管理措施,包括肽类和微小RNA疗法。这项研究为冠状动脉粥样硬化的现有知识提供了更新的见解,并强调了有效预防、管理和开发新的干预方法以克服这一慢性流行病的必要性。